Home Newsfeeds BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

BMO Capital analyst Daniel Jester maintains Workiva (NYSE:WK) with a Outperform and raises the price target from $76 to $88.

byBenzinga Newsdesk

December 6, 2022

1 minute read

BMO Capital analyst Daniel Jester maintains Workiva (NYSE:WK) with a Outperform and raises the price target from $76 to $88.

News
Tech

GM’s Mary Barra On Tesla-Like Price Cuts — ‘Price Them Right To Begin With’

By Anan Ashraf

April 26, 12:55 AM

General Motors Co. (NYSE:GM) CEO Mary Barra addressed the issue of price cuts in the company’s first-quarter earnings…

Why Is Healthcare Enterprise Centene Stock Trading Higher Today?

By Vandana Singh

December 12, 12:21 PM

Centene Corporation (NYSE: CNC) outlined its 2024 financial guidance and provided updates on its

CNC

Analyst Ratings

Analyst Ratings for Cushman & Wakefield

By Benzinga Insights

June 28, 1:00 PM

Within the last quarter, Cushman & Wakefield (NYSE:CWK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

CWK

“DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination” – Marijuana Moment

By Benzinga Newsdesk

January 4, 12:41 PM

A top Drug Enforcement Administration (DEA) has affirmed that spores that produce so-called magic mushrooms are not, on their own, federally prohibited.DEA's Drug & Chemical Evaluation Section Chief Terrence Boos was

CMPS

BMO Capital Maintains Outperform on Workiva, Raises Price Target to $88

Related Posts

GM’s Mary Barra On Tesla-Like Price Cuts — ‘Price Them Right To Begin With’

Why Is Healthcare Enterprise Centene Stock Trading Higher Today?

Analyst Ratings for Cushman & Wakefield

“DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination” – Marijuana Moment